论文部分内容阅读
目的:观察利拉鲁肽治疗2型糖尿病(T2DM)合并肥胖患者的降糖及减重作用,探讨合并肥胖的T2DM新的治疗思路.方法:超重和肥胖的T2DM患者38例,入组前口服降糖药物或应用胰岛素治疗血糖控制不达标,按体质指数(BMI)分为两组,A组为超重组(BMI 24~28 kg·m-2)18例、B组为肥胖组(BMI≥28 kg·m-2)20例,两组均加用利拉鲁肽治疗12周,观察治疗前后两组患者身高、体质量和BMI;2 h空腹和餐后2 h血糖(FPG,2hPG)、糖化血红蛋白(HbA1c),空腹(FINS)和餐后2 h胰岛素(2hINS)、空腹(FCP)和餐后2 hC肽(2hCP);以及胰岛素抵抗指数(HOMA-IR)和胰岛β细胞分泌功能指数(HO-MA-β).结果:治疗后两组患者的HbA1c、FBG、2hPG、FCP、2hCP及HOMA-β、HOMA-IR等指标均较治疗前明显改善(P0.05).治疗后B组患者体质量和BMI较治疗前下降明显(P0.05).结论:超重和肥胖T2DM患者,加用利拉鲁肽治疗后,可有效地控制血糖,改善胰岛素抵抗,而肥胖患者体质量较治疗前有明显下降.“,”Objective:To observe the hypoglycemic and weight loss effects of liraglutide in type 2 diabetes mellitus (T2DM) com-plicated with obesity, and explore new treatment strategies for T2DM complicated with obesity. Methods: Totally 38 T2DM patients complicated with obesity with dissatisfactory blood sugar control treated with oral hypoglycemic drugs or insulin were enrolled and divid-ed into group A ( overweight group, 28 kg·m-2 >BMI≥24 kg·m-2 , 18 cases) and group B ( obesity group, BMI≥28 kg·m-2 , 20 cases) according to the body mass index ( BMI) . Liraglutide was used in all the participants for 12 weeks. The height, weight, BMI,HbA1c, fasting blood glucose(FBG),2-hour postprandial blood glucose(2hPG), fasting insulin(FINS),2-hour postprandial in-sulin (2hPINS),fast-c peptide(FCP), 2-hour postprandial c-peptide(2hCP) and insulin resistance index (HOMA-IR), pancreaticβcell function index( HOMA-β) of the two groups were detected before and after the liraglutide treatment. Results:After the treatment with liraglutide, HbA1c, FPG, 2hPG, FCP,2hCP,HOMA-β,HOMA-IR were significantly decreased (P0. 05). However, the body weight in group B was sig-nificantly lower than before (P0. 05). Conclusion: Liraglutide can effectively control blood glucose level, ameliorate insulin resistance and obviously decrease the body weight in the T2DM patients com-plicated with obesity.